Healthcare >> Analyst Interviews >> May 3, 2004

LARGE & MID-CAP BIOTECHNOLOGY COMPANIES: LEI ZHONG – RODMAN & RENSHAW

LEI ZHONG is a Senior Biotechnology Analyst at Rodman & Renshaw. Prior to joining Rodman, Dr. Zhong was an Emerging Equity Analyst in Biotechnology with UBS Investment Bank where he covered large and mid- cap biotechnology companies. Dr. Zhong obtained his PhD in Life Sciences from the Rockefeller University in New York where he conducted researches in the areas of immunology, virology, molecular biology and structural biology. Dr. Zhong is a lead author of numerous peer- reviewed scientific journals and a speaker at academic research conferences at both national and international levels. He is focused on mid-cap biotechnology companies with novel technologies and early or late stage clinical products under development. Profile
TWST: May we start with a quick overview of your coverage at Rodman &

Renshaw?

Dr. Zhong: I joined Rodman about a month and a half ago, and as we speak

I don't have any official coverage.